Skip to content

Comparing Skin Conductance and Nol-index

Nociceptive Monitoring With Skin Conductance and Nol-index in Moderate-to-high Risk Cardiovascular Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04138966
Enrollment
10
Registered
2019-10-25
Start date
2019-10-20
Completion date
2020-12-20
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Anesthesia, Monitoring, Vascular Diseases, Cardiac Disease

Brief summary

Comparison of twà different nociception monitors during general anesthesia

Detailed description

Analgesia remains a challenge in anesthesia. Several monitors have shown potential in detecting insufficient analgesia during general anesthesia, but they have not been investigated in patients undergoing cardiac and vascular surgery. In this study, we will compare skin conductance (Medstorm, Norway) and nol-index (Medasense, Israel) w during noxious and non-noxious stimuli. This study is carried out on patients included in another study (Nol-Index Guided Remifentanil Analgesia Versus Standard Analgesia During Moderate-to-High Risk Cardiovascular Surgery).

Interventions

DEVICENol-Index

Multiparametric monitor that studies that establishes an index as a surrogate to nociception

Measures skin conductance as a surrogate to nociception

Sponsors

Erasme University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* moderate-to-high risk cardiac or vascular surgery * ASA 2-4

Exclusion criteria

* chronic arrhythmia (e.g. atrial fibrillation) * aortic insufficiency * pacemaker * implanted defibrillator * valve surgery

Design outcomes

Primary

MeasureTime frameDescription
Nol-Index response1 to 2 hoursNol-Index (diminsenliss value from 0 to 100) will be assessed during noxious and non noxious stimuli
Skin conductance response1 to 2 hoursPeaks per second change during noxious and non noxious stimuli

Countries

Belgium

Contacts

Primary ContactSean Coeckelenbergh, MD
secoecke@ulb.ac.be32 (0) 2 555 39 19
Backup ContactLuc Barvais, MD, PhD
32 (0) 2 555 39 19

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026